NEW YORK (GenomeWeb) – Biotech firm MeMed today announced it has been awarded a $9.2 million contract to complete the development of its point-of-care platform for distinguishing bacterial from viral infections.

The grant is from the Defense Threat Reduction Agency, a branch of the US Department of Defense. In collaboration with researchers and clinicians, the firm has spent the past eight years studying changes in the human immune system when it fights infections, in order to develop a human immune signature that recognizes the difference between bacterial and viral infections.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.